New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
06:52 EDTMRK, INCYIncyte and Merck enter into collaboration for INCB24360 and MK-3475
Incyte (INCY) announced that it has entered into a clinical trial collaboration agreement with Merck (MRK), through a Merck subsidiary, to evaluate the safety and efficacy of Incyte's oral indoleamine dioxygenase-1 inhibitor, INCB24360, and Merck's investigational anti-PD-1 immunotherapy, MK-3475, in a Phase I/II study in previously treated metastatic and recurrent non-small cell lung cancer, or NSCLC, and other advanced or metastatic cancers. Both INCB24360 and MK-3475 are part of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer.
News For INCY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:02 EDTMRKMerck, Syndax to collaborate on immuno-oncology study
Syndax Pharmaceuticals (SNDX), and Merck (MRK) announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s KEYTRUDA, the first anti-PD-1 therapy approved in the United States. The Phase 1b/2 study will evaluate this novel combination regimen in patients with either advanced non-small cell lung cancer or melanoma. The study is expected to begin enrolling patients in the second half of 2015. The financial terms and additional details of the agreement between Syndax and Merck, through a subsidiary, were not disclosed. The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial. The planned Phase 1b/2 multicenter, open-label clinical trial will be conducted in two parts. The Phase 1b portion is designed to determine the safety and tolerability of entinostat in combination with KEYTRUDA. The Phase 2 portion is designed to evaluate the efficacy of entinostat combined with KEYTRUDA in patients with advanced NSCLC and melanoma.
March 30, 2015
08:47 EDTMRKOrexigen CCO Booth to leave, Cannell appointed CCO
Subscribe for More Information
March 26, 2015
10:10 EDTINCYAnalyst calls sharp pullback in biotech stocks 'misguided'
Subscribe for More Information
08:31 EDTMRKMerck announces collaboration with American Diabetes Association
Merck announced a collaboration with the American Diabetes Association. The collaboration aims to educate adults with diabetes about their increased risk for potentially serious health problems, including pneumococcal pneumonia, influenza and hepatitis B, making it important for people with Type 1 or Type 2 diabetes to talk to their health care professional about these diseases.
06:45 EDTINCYBiotech valuation concerns 'misguided,' says Piper Jaffray
Subscribe for More Information
March 25, 2015
07:28 EDTMRKOptions expected to be active
Subscribe for More Information
March 24, 2015
19:40 EDTMRKOn The Fly: After Hours Movers
Subscribe for More Information
17:02 EDTMRKMerck announces new $10B share repurchase program
Merck announced that its board of directors has authorized additional purchases of up to $10B of Merck’s common stock for its treasury. The treasury stock purchase has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. With this announcement, the company’s total outstanding share repurchase authorization is now approximately $11.7B, which includes approximately $1.7B in authorized repurchases remaining under the program previously announced on May 1, 2013. Merck continues to expect average diluted shares outstanding will be approximately 2.86B in 2015.
17:00 EDTMRKMerck announces new $10B share repurchase program
Subscribe for More Information
16:00 EDTMRKOptions Update; March 24, 2015
iPath S&P 500 VIX Short-Term Futures down 10c to 25.14 Option volume leaders: AAPL TSLA TWTR GILD FB AMAT GOOG C MRK GILD according to Track Data.
08:31 EDTMRKMerck: Phase 3 KEYNOTE-006 study met co-primary endpoints, will be stopped early
Subscribe for More Information
March 23, 2015
09:45 EDTMRKUBS to hold a field trip
Subscribe for More Information
07:17 EDTMRKAmerican Academy of Dermatology to hold annual meeting
73rd Annual Meeting of AAD is being held in San Francisco on March 20-24.
March 20, 2015
07:41 EDTMRKAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 17, 2015
05:32 EDTINCYIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use